Concomitant administration of hepatitis A vaccine with measles/mumps/ rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 8, 2013, Pages 1691-1697

  Yetman, Robert J ^a   Shepard, Julie S ^b   Duke, Anton ^c   Stek, Jon E ^d   Petrecz, Maria ^d   Klopfer, Stephanie O ^d   Kuter, Barbara J ^d   Schödel, Florian P ^d,e   Lee, Andrew W ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b Ohio Pediatrics Inc   (United States)

^c Arkansas Pediatrics   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Philimmune LLC   (United States)

Author keywords

Concomitant use; Hepatitis A; Immunogenicity; Measles; Mumps; Pneumococcal; Rubella; Safety; Vaccine; Varicella

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; HEPATITIS A VACCINE; PNEUMOCOCCUS VACCINE;

ABSCESS; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRONCHOPNEUMONIA; CELLULITIS; CHICKENPOX; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DEHYDRATION; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE CONVULSION; FEMALE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEPATITIS A; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; IRRITABILITY; MALE; MEASLES; MULTICENTER STUDY; MUMPS; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

CONCOMITANT USE; HEPATITIS A; IMMUNOGENICITY; MEASLES; MUMPS; PNEUMOCOCCAL; RUBELLA; SAFETY; VACCINE; VARICELLA;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHICKENPOX VACCINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; PNEUMOCOCCAL VACCINES; VACCINATION; VACCINES, COMBINED;

EID: 84882968684     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24873     Document Type: Article

References (15)

1. U.S. Package Circular. VAQTA™ (Hepatitis A Vaccine, Inactivated): February 2003. Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM110049.pdf. Accessed: 03-Apr-2013.
2. Fiore AE, Wasley A, Bell BP; Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR07):1-23; PMID:16708058
3. Werzberger A, Kuter B, Shouval D, Mensch B, Brown L, Wiens B, et al. Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial. J Hepatol 1993; 18(Suppl 2):S46-50; PMID:8182273; http://dx.doi.org/10.1016/S0168-8278(05)80378-2
4. Linglöf T, van Hattum J, Kaplan KM, Corrigan J, Duval I, Jensen E, et al. An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immuno-genicity. Vaccine 2001; 19:3968-71; PMID:11427272; http://dx.doi.org/10.1016/S0264-410X(01)00134-7
5. Hornick R, Tucker R, Kaplan KM, Eves KA, Banerjee D, Jensen E, et al. A randomized study of a flexible booster dosing regimen of VAQTA in adults: safety, tol-erability, and immunogenicity. Vaccine 2001; 19:4727-31; PMID:11535323; http://dx.doi.org/10.1016/S0264-410X(01)00224-9
6. Black S, Shinefield H, Hansen J, Lewis E, Su L, Coplan P. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. Vaccine 2004; 22:766-72; PMID:14741171; http://dx.doi.org/10.1016/j.vaccine.2003.08.034
7. Wallace MR, Brandt CJ, Earhart KC, Kuter BJ, Grosso AD, Lakkis H, et al. Safety and immunogenic-ity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39:1207-13; PMID:15486846; http://dx.doi.org/10.1086/424666
8. U.S. Package Circular. ProQuad™ (Measles, Mumps, Rubella and Varicella [Oka/Merk] Virus Vaccine Live): October 2007. Available at: http://www.fda. gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ ucm123793.pdf. Accessed: 03-Apr-2013.
9. Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR03):1-12; PMID:20448530
10. U.S. Package Circular. Prevnar™ (Pneumococcal 7-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]): 2005. Available at: http://www.fda. gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM137038.pdf. Accessed: 03-Apr-2013.
11. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR09):1-35; PMID:11055835
12. Centers for Disease Control and Prevention. Child, Adolescent & "Catch-up" Immunization Schedules. Available at: http://www.cdc.gov/ vaccines/schedules/hcp/child-adolescent.html. Accessed: August 22, 2012.
13. Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H, et al.; Pediatric Study Group for VAQTA. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J 2006; 25:912-9; PMID:17006287; http://dx.doi.org/10.1097/01. inf.0000238135.01287.b9
14. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L; Centers for Disease Control and Prevention. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47(RR-8):1-57; PMID:9639369
15. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26; PMID:4023479; http://dx.doi.org/10.1002/sim.4780040211